GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Repligen RGEN · USD

Health Care · US listing · 🇺🇸 United States

Compare

178.94

+3.14%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$738.3m

FY2016FY2025

Net income

$48.9m

FY2016FY2025

Free cash flow

$93.9m

FY2016FY2025

Shareholders' equity

$2.11bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$738.3m$634.4m$638.8m$801.5m$670.5m$366.3m$270.2m$194.0m$141.2m$104.5m
Gross profit$347.6m$274.6m$284.2m$455.7m$391.3m$194.4m$138.2m$108.1m$74.2m$57.4m
Research and development$54.2m$43.2m$42.7m$43.9m$34.3m$19.7m$19.4m$15.8m$8.7m$7.4m
Operating income$82.8m−$35.1m$56.2m$224.7m$167.2m$81.3m$40.1m$26.0m$13.7m$16.0m
Net income$48.9m−$25.5m$41.6m$186.0m$128.3m$59.9m$21.4m$16.6m$28.4m$11.7m
Diluted earnings per share0.87-0.460.743.262.221.090.400.360.640.34

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$2.95bn$2.83bn$2.82bn$2.53bn$2.36bn$1.90bn$1.40bn$139.4m$120.4m$288.9m
Cash and short-term investments$767.6m$757.4m$751.3m$623.8m$603.8m$717.3m$528.4m$193.8m$173.8m$141.8m
Total liabilities$843.6m$856.9m$853.2m$620.9m$608.3m$373.7m$340.3m$159.1m$151.9m$120.1m
Debt$563.8m$525.6m$579.6m$284.6m$255.3m$243.7m$232.8m$103.5m$99.3m$95.3m
Shareholders' equity$2.11bn$1.97bn$1.97bn$1.91bn$1.75bn$1.53bn$1.06bn$615.6m−$31.5m$168.8m
Shares outstanding57m56m56m57m58m55m53m46m44m34m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$117.4m$175.4m$113.9m$172.1m$119.0m$62.6m$67.2m$32.8m$17.5m$7.5m
Capital spending−$23.5m−$32.9m−$39.0m−$133.3m−$67.1m−$26.3m−$23.2m−$14.0m−$5.5m−$4.3m
Free cash flow$93.9m$142.5m$74.9m$38.7m$51.9m$36.3m$44.1m$18.7m$12.0m$3.2m
Dividends paid——−$565.7m−$17.0m−$2.9m—−$490,000———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$204.1m$194.3m$197.9m$188.8m$182.4m$169.2m$167.5m$154.9m
Gross profit$108.4m$98.5m$93.4m$100.5m$91.1m$90.8m$38.8m$77.5m
Operating income$22.1m$18.0m$24.5m$22.5m$19.7m$13.2m−$33.1m−$7.8m
Net income$5.0m$8.3m$13.3m$14.9m$14.9m$5.8m−$33.9m−$654,000
Diluted earnings per share0.090.150.240.260.260.10-0.60-0.01
Cash from operations$32.0m$28.0m$25.0m$48.0m$28.0m$15.0m$39.0m$49.0m
Capital spending−$5.0m−$4.0m−$8.0m−$5.0m−$7.0m−$4.0m−$6.0m−$7.0m
Free cash flow$27.0m$24.0m$17.0m$43.0m$21.0m$11.0m$33.0m$42.0m
Total assets$2.95bn$2.93bn$2.95bn$2.92bn$2.90bn$2.85bn$2.83bn$2.83bn
Cash and short-term investments$810.4m$784.5m$767.6m$748.7m$708.9m$697.2m$757.4m$784.0m
Debt$570.4m$567.7m$563.8m$557.2m$549.8m$544.8m$540.7m$533.8m
Shareholders' equity$2.11bn$2.11bn$2.11bn$2.08bn$2.06bn$1.99bn$1.97bn$2.02bn

Financial ratios

Data as of 9 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin47.1%43.3%44.5%56.9%58.3%53.1%
Operating margin11.6%-1.0%8.8%27.5%24.6%19.5%
Net margin6.6%-4.0%6.5%23.2%19.1%16.4%
Return on equity2.3%-1.3%2.1%9.7%7.3%3.9%
Return on assets1.7%-0.9%1.5%7.3%5.4%3.1%
Free cash flow yield1.5%2.3%1.7%3.3%2.0%1.0%
Revenue growth16.4%-0.7%-20.3%19.5%83.1%35.5%
Earnings growth-291.6%-161.4%-77.6%45.0%114.1%179.9%
Current ratio8.37x8.41x7.02x2.47x2.48x2.83x
Debt to equity0.27x0.27x0.30x0.15x0.15x0.16x
Equity ratio71.4%69.7%69.8%75.5%74.2%80.4%
Interest coverage3.69x-0.28x5.61x74.00x12.96x5.88x
R&D as a share of sales7.3%6.8%6.7%5.5%5.1%5.4%
Buybacks as a share of market value-0.8%-0.4%2.3%1.1%-4.9%-3.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-2.7%15.0%24.3%
Operating income-28.3%0.4%19.6%
Net income-35.9%-4.0%18.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin45.3%48.4%50.6%51.1%
Operating margin3.5%11.7%15.0%14.8%
Net margin1.7%8.9%11.4%11.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings189.4-316.3241.452.0119.2175.9228.9146.956.890.7
Price to sales12.612.715.712.122.828.818.112.611.410.1

Market value over time

30 Nov 2016 to 8 Oct 2026, in USD

$1.10bn$9.28bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return7%-19%12%-40%40%107%83%44%8%17%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.